O. Derbel

发表

Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program

J. Blay, F. Bertucci, B. Bui, 2013, BMC Cancer.

Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery

A. LeMaistre, M. Rivoire, P. Méeus, 2013, BMC Cancer.

An unusual giant cell tumor of the thyroid: case report and review of the literature.

J. Blay, C. Chassagne‐Clément, A. Decouvelaere, 2013, The Journal of clinical endocrinology and metabolism.

Giant-cell tumor of bone, anti-RANKL therapy.

J. Blay, A. Decouvelaere, P. Cassier, 2012, BoneKEy reports.

Does Molecular Genotype Provide Useful Information in the Management of Radioiodine Refractory Thyroid Cancers? Results of a Retrospective Study

F. Borson‐Chazot, A. Giraudet, P. Bringuier, 2016, Targeted Oncology.

Outcome of patients with advanced solitary fibrous tumors: the Centre Léon Bérard experience

J. Blay, I. Ray-Coquard, P. Cassier, 2013, BMC Cancer.

Giant cell tumors of bone

J. Blay, O. Derbel, 2015 .

A single dose pegfilgrastim for supporting neutrophil recovery in patients treated for high-risk acute myeloid leukemia by the EMA 2000 schedule

X. Thomas, M. Elhamri, F. Barraco, 2010, Hematology.

Unusual adverse event with vandetanib in metastatic medullary thyroid cancer.

J. Peix, O. Derbel, C. de la Fouchardière, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pazopanib for the treatment of soft-tissue sarcoma

J. Blay, I. Ray-Coquard, D. Ranchère‐Vince, 2012, Clinical pharmacology : advances and applications.

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.

I. Bièche, F. Clatot, F. André, 2022, The Lancet. Oncology.

Results of combined treatment of anaplastic thyroid carcinoma (ATC)

J. Droz, F. Borson‐Chazot, C. Bournaud, 2011, BMC Cancer.

KIT and KIT Inhibitors

J. Blay, I. Ray-Coquard, A. Dufresne, 2013 .

Systemic Therapy in Sarcomas: Integrating the Old with the New CHAIR

J. Blay, I. Ray-Coquard, O. Derbel, 2013 .

Location of Mutation in BRCA2 Gene and Survival in Patients with Ovarian Cancer

P. Chappuis, P. Meraldi, M. Stern, 2017, Clinical Cancer Research.

Survival impact of centralization and clinical guidelines for soft tissue sarcoma (A prospective and exhaustive population-based cohort)

J. Blay, P. Biron, I. Ray-Coquard, 2017, PloS one.

Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program

J. Blay, F. Bertucci, B. Bui, 2013, BMC Cancer.

Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProfiLER programme.

J. Blay, A. Viari, I. Ray-Coquard, 2019, European journal of cancer.

Concomitant occurrence of pulmonary invasive aspergillosis and Pneumocystis pneumonia during FOLFIRINOX chemotherapy for pancreatic carcinoma.

P. Méeus, J. Péron, O. Derbel, 2013, Pancreas.

The clinician's perspective on sarcoma pathology reporting: impact on treatment decisions?

J. Blay, I. Ray-Coquard, O. Derbel, 2014, Pathology.

Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery

A. LeMaistre, M. Rivoire, P. Méeus, 2013, BMC Cancer.

Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers.

I. Ray-Coquard, O. Trédan, E. Kalbacher, 2019, Gynecologic oncology.

Predictive factors for prolonged response to olaparib as maintenance therapy in ovarian cancer patients with BRCA mutations.

I. Ray-Coquard, O. Trédan, E. Kalbacher, 2018 .

Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated with Metronomic Cyclophosphamide: A Clinical and Translational Prospective Study

I. Treilleux, I. Ray-Coquard, C. Caux, 2023, Breast cancer.

Eight years tumor control with pazopanib for a metastatic resistant epithelioid hemangioendothelioma

J. Blay, A. Decouvelaere, O. Derbel, 2015, Clinical Sarcoma Research.

Adhesion to Clinical Practices Guidelines (CPG'S) and Role on Survival for Soft Tissue Sarcoma Patients. Analysis of a Population Based Cohort from Rhone-Alpes Region

J. Blay, D. Vince-Ranchère, I. Ray-Coquard, 2012 .

Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2–14)

F. Penault-Llorca, J. Lemonnier, F. Kwiatkowski, 2019, Breast.

The histone deacetylase inhibitor panobinostat is active in patients with advanced pretreated ovarian sex-cord tumors.

J. Blay, I. Treilleux, I. Ray-Coquard, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Pazopanib for the treatment of soft-tissue sarcoma

J. Blay, I. Ray-Coquard, P. Schöffski, 2012, Clinical pharmacology : advances and applications.

Concomitant occurrence of pulmonary invasive aspergillosis and Pneumocystis pneumonia during FOLFIRINOX chemotherapy for pancreatic carcinoma.

J. Péron, O. Derbel, C. de la Fouchardière, 2013, Pancreas.

A single dose pegfilgrastim for supporting neutrophil recovery in patients treated for high-risk acute myeloid leukemia by the EMA 2000 schedule

X. Thomas, M. Elhamri, F. Barraco, 2010, Hematology.